Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy
The results of recent studies investigating the role of platinum-based chemotherapy (PBCT) in metastatic triple-negative breast cancer (mTNBC) were conflicting. We retrospectively investigated a large cohort (n = 379) of mTNBC to re-evaluate the role of platinums. Longer PFS was found in patients wi...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4767497/ https://www.ncbi.nlm.nih.gov/pubmed/26447756 |
_version_ | 1782417827960979456 |
---|---|
author | Zhang, Jian Fan, Minhao Xie, Jie Wang, Zhonghua Wang, Biyun Zhang, Sheng Wang, Leiping Cao, Jun Tao, Zhonghua Li, Ting Hu, Xichun |
author_facet | Zhang, Jian Fan, Minhao Xie, Jie Wang, Zhonghua Wang, Biyun Zhang, Sheng Wang, Leiping Cao, Jun Tao, Zhonghua Li, Ting Hu, Xichun |
author_sort | Zhang, Jian |
collection | PubMed |
description | The results of recent studies investigating the role of platinum-based chemotherapy (PBCT) in metastatic triple-negative breast cancer (mTNBC) were conflicting. We retrospectively investigated a large cohort (n = 379) of mTNBC to re-evaluate the role of platinums. Longer PFS was found in patients with PBCT than those with non-PBCT (7.8 vs. 4.9 months, P < 0.001) as first-line chemotherapy, but no statistical difference of OS was observed. Compared with other kinds of platinum, cisplatin-based regimens as the first-line chemotherapy showed better PFS (8.0 vs. 4.3 months, P = 0.03) and better ORR. Introduction of ≥2 lines, rather than 1 line, of PBCT can result in better OS when compared with no introduction of PBCT during the whole treatment. If considering the timing of intervention of PBCT, first-line introduction and later line introduction of PBCT did not make any difference in OS among patients with only one line PBCT during the whole treatment. We concluded that PBCT with only 1 line during the whole treatment might not be necessary for unselected mTNBC with the exception of an urgent demand to control disease or symptoms, however, ≥2 lines of PBCT did prolong OS. |
format | Online Article Text |
id | pubmed-4767497 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-47674972016-03-25 Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy Zhang, Jian Fan, Minhao Xie, Jie Wang, Zhonghua Wang, Biyun Zhang, Sheng Wang, Leiping Cao, Jun Tao, Zhonghua Li, Ting Hu, Xichun Oncotarget Clinical Research Paper The results of recent studies investigating the role of platinum-based chemotherapy (PBCT) in metastatic triple-negative breast cancer (mTNBC) were conflicting. We retrospectively investigated a large cohort (n = 379) of mTNBC to re-evaluate the role of platinums. Longer PFS was found in patients with PBCT than those with non-PBCT (7.8 vs. 4.9 months, P < 0.001) as first-line chemotherapy, but no statistical difference of OS was observed. Compared with other kinds of platinum, cisplatin-based regimens as the first-line chemotherapy showed better PFS (8.0 vs. 4.3 months, P = 0.03) and better ORR. Introduction of ≥2 lines, rather than 1 line, of PBCT can result in better OS when compared with no introduction of PBCT during the whole treatment. If considering the timing of intervention of PBCT, first-line introduction and later line introduction of PBCT did not make any difference in OS among patients with only one line PBCT during the whole treatment. We concluded that PBCT with only 1 line during the whole treatment might not be necessary for unselected mTNBC with the exception of an urgent demand to control disease or symptoms, however, ≥2 lines of PBCT did prolong OS. Impact Journals LLC 2015-10-03 /pmc/articles/PMC4767497/ /pubmed/26447756 Text en Copyright: © 2015 Zhang et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Clinical Research Paper Zhang, Jian Fan, Minhao Xie, Jie Wang, Zhonghua Wang, Biyun Zhang, Sheng Wang, Leiping Cao, Jun Tao, Zhonghua Li, Ting Hu, Xichun Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy |
title | Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy |
title_full | Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy |
title_fullStr | Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy |
title_full_unstemmed | Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy |
title_short | Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy |
title_sort | chemotherapy of metastatic triple negative breast cancer: experience of using platinum-based chemotherapy |
topic | Clinical Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4767497/ https://www.ncbi.nlm.nih.gov/pubmed/26447756 |
work_keys_str_mv | AT zhangjian chemotherapyofmetastatictriplenegativebreastcancerexperienceofusingplatinumbasedchemotherapy AT fanminhao chemotherapyofmetastatictriplenegativebreastcancerexperienceofusingplatinumbasedchemotherapy AT xiejie chemotherapyofmetastatictriplenegativebreastcancerexperienceofusingplatinumbasedchemotherapy AT wangzhonghua chemotherapyofmetastatictriplenegativebreastcancerexperienceofusingplatinumbasedchemotherapy AT wangbiyun chemotherapyofmetastatictriplenegativebreastcancerexperienceofusingplatinumbasedchemotherapy AT zhangsheng chemotherapyofmetastatictriplenegativebreastcancerexperienceofusingplatinumbasedchemotherapy AT wangleiping chemotherapyofmetastatictriplenegativebreastcancerexperienceofusingplatinumbasedchemotherapy AT caojun chemotherapyofmetastatictriplenegativebreastcancerexperienceofusingplatinumbasedchemotherapy AT taozhonghua chemotherapyofmetastatictriplenegativebreastcancerexperienceofusingplatinumbasedchemotherapy AT liting chemotherapyofmetastatictriplenegativebreastcancerexperienceofusingplatinumbasedchemotherapy AT huxichun chemotherapyofmetastatictriplenegativebreastcancerexperienceofusingplatinumbasedchemotherapy |